NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.
Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines
Latest in Molecular Imaging
EANM: Is ‘research fragmentation’ holding back nuclear medicine?
October 21, 2026
Telix posts revenue growth in Q3
October 21, 2026
FAPI-PET detects more HCC lesions than FDG-PET
October 20, 2026



![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)







![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)






